Shots:
- The approval is based on P-lll VIALE-A & VIALE-C studies and updated data from the P-Ib M14-358 and the P-I/II M14-387 studies. The P-III studies involve assessing of Venclexta (400mg & 600mg, qd) + azacitidine & LDAC vs PBO + azacitidine & LDAC in 431 & 211 people with previously untreated AML who are ineligible for intensive CT respectively
- VIALE-A results: Reduction in the risk of death (34%), m-OS (14.7 vs 9.6mos.), CR rate (37% vs 18%); CR+CRh rate (65% vs 23%), median duration (7.6 mos.). VIALE-C results: CR rate (27% vs 7.4%); DOCR (11.1mos. vs 8.3mos.); m-OS (7.2mos. vs 4.1mos.). In 2018, the US FDA has granted accelerated approval for AML
- This is the second time that Venclexta has been reviewed under the FDA’s new RTOR and Assessment Aid pilot program. Additionally, the FDA has granted five BTD for Venclexta, two of which are for people with previously untreated AML ineligible for intensive CT
Source 1, Source 2 to read full press release/ article | Ref: Abbvie & Roche | Image: Leukemia & Lymphoma Society
The post AbbVie and Roche’s Venclexta (venetoclax) Receive the US FDA’s Approval for Acute Myeloid Leukemia first appeared on PharmaShots.
